AMRX earnings analysis
What we found in AMRX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Amneal Pharmaceuticals reported Q1 2026 earnings with a revenue of $722.5 million and an EPS of $0.19, both exceeding analyst expectations. The results show a 3.9% revenue growth year-over-year, driven by gains in the Specialty segment, although one segment saw a revenue decline. Guidance for FY 2026 remains optimistic with anticipated revenue between $3.05 billion and $3.15 billion and adjusted EPS of $0.95 to $1.05.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Increased Year-Over-Year
- Net revenue for Q1 2026 was $722.5 million, up 3.9% from $695.4 million in Q1 2025.
- Strong EPS Performance
- Reported EPS of $0.19, exceeding the estimate of $0.17.
- Specialty Segment Growth
- Specialty revenue rose 23.1% to $133.3 million, largely due to increased sales of CREXONT® and BREKIYA®.
- Reduced Cost of Goods Sold
- Cost of goods sold decreased 8.4% year-over-year, contributing to a gross margin increase to 44.3%.
- Affirmed FY 2026 Guidance
- Maintains revenue guidance of $3.05B to $3.15B and EPS guidance of $0.95 to $1.05.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Pending Acquisition of Kashiv
- The acquisition may not be completed on schedule or at all, potentially impacting future growth.
- Increased Litigation Costs
- $35.9 million paid in litigation settlements related to the Nationwide Opioids Settlement Agreement in Q1 2026.
- Foreign Trade Tariffs Risks
- Changes in trade policies and tariffs may increase costs or disrupt supply chains.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.19
- Gross margin
- 44.3%
- Operating margin
- 19.6%
- Segment
- Affordable Medicines
- Segment
- Specialty
- Segment
- AvKARE
What they said about what is next.
Affirmed previously announced increased guidance for FY 2026.
The filing reads better than the one before it.
What came before.
- 10-K · February 27, 2026
- Amneal reported fiscal 2025 revenue of approximately $3.019 billion (quarters summed) with Q4 revenue of $814.3M (vs. est. $810.7M) and continued margin stability (gross ~36.9%). The company is executing a strategy…
- 10-Q · November 6, 2025
- Amneal reported quarterly revenue of $784,513,000 (up $82,045,000 vs. $702,468,000 a year ago) with gross profit of $273,974,000 but compressed gross margin to 34.9% (from 38.4% prior year). Operating income declined to…
- 10-Q · August 7, 2025
- Amneal reported Q2 net revenue of $724,508,000, up $22,728,000 (+3.2%) versus Q2 2024, with gross profit rising to $286,253,000 and gross margin expanding to 39.5% from 35.6%. Operating income improved to $111,372,000…
- 10-Q · August 9, 2024
- Amneal Pharmaceuticals reported strong growth in Q2 2024, with revenues of $701.78 million, up 17.3% from the previous quarter and 17.3% year-over-year. However, despite the revenue increase, the net income was $5.99…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AMRX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever